Trial · NCT06049186
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Live birth during the period of ovulation induction | 18 months | Live birth will be defined as the delivery of one or more living infants (≥22 week's gestation or birth weight more than 500g). The outcome could be assessed by clinical data and clinical diagnosis. |
| Secondary | Fasting blood glucose (FBG) | Baseline period and 3 months | A laboratory test that determines the level of glucose in the blood after an overnight fast, used especially to diagnose diabetes and prediabetes. The normal interval is 3.9-6.1mmol/L. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Fasting insulin (FINS) | Baseline period and 3 months | The level of insulin in the blood during fasting (usually in the morning when fasting). The normal interval is 5\~20 μIU. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Oral glucose tolerance test (OGTT) | Baseline period and 3 months | An oral glucose tolerance test (OGTT) is a diagnostic tool used to evaluate how an individual's body metabolizes sugar. Often used to diagnose diabetic conditions, an oral glucose tolerance test requires minimal preparatory measures and may be safely administered during pregnancy. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Insulin release test (IRT) | Baseline period and 3 months | Quantitative oral glucose during fasting increases blood glucose and stimulates pancreatic β cells to release insulin. By measuring plasma insulin levels during fasting and 0.5h, 1h, 2h, and 3h after taking sugar, we can understand the secretion and reserve function of pancreatic β cells, which is also helpful for the classification of diabetes mellitus and guide treatment. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Blood lipid | Baseline period and 3 months | Lipid related indicators include cholesterol, triglycerides. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Kidney function index | Baseline period and 3 months | Blood tests that are included in the kidney function test include measuring for creatinine and blood urea nitrogen (BUN). The outcome could be assessed by clinical data and clinical test. |
| Secondary | Liver function index | Baseline period and 3 months | Liver function index includes alanine aminotransferase (ALT), alkaline phosphatase (ALP) . The outcome could be assessed by clinical data and clinical test. |
| Secondary | Free testosterone (FT) | Baseline period and 3 months | The average serum testosterone concentration is 0.43ng/ml, the high limit is 0.68ng/ml, if more than 0.7ng/m1 (equal to 2.44nmol/L), it is called hypertestosterone, or hyperandrogenemia. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Total testosterone (TT) | Baseline period and 3 months | The normal range of female testosterone is 0.1-0.75ng /ml, testosterone is the main sex hormone of the human body, men and women have secretion, male testosterone secretion is 20-30 times the amount of female testosterone secretion, it is very important to maintain the second sexual characteristics, bone and muscle strength. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Sex Hormone Binding Globulin (SHBG) | Baseline period and 3 months | A globulin synthesized by liver cells that can bind sex hormones, also known as testosterone - estrogen binding globulin or steroidal binding protein, is an important carrier of sex hormones, which can have an important impact on the regulation of sex hormone levels and bioavailability in the body. Clinical detection of SHBG level can provide scientific reference value for disease detection and judgment. The normal interval is 20-130nmol/L for women. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Liver transient elastography(TE) | Baseline period and 3 months | TE may be used to monitor disease progression or regression via serial measurements and to guide further management including treatment. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Weight | Baseline period and 3 months | Unit: kilogram (kg). The outcome could be assessed by clinical data and clinical test. |
| Secondary | Height | Baseline period and 3 months | Unit: meter (m). The outcome could be assessed by clinical data and clinical test. |
| Secondary | Body Mass Index (BMI) | Baseline period and 3 months | BMI = weight (in kg)/ height\^2 (in m\^2). |
| Secondary | Waist circumference | Baseline period and 3 months | Unit: centimeter (cm). The outcome could be assessed by clinical data and clinical test. |
| Secondary | Body fat | Baseline period and 3 months | Body fat is measured by body fat scale. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Lean body weight | Baseline period and 3 months | Lean body weight refers to the total weight of organs, bones, and muscles. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Blood pressure (BP) | Baseline period and 3 months | Blood pressure is a measurement of the force of blood against the arterial walls when the heart pumps. The pressure is measured in millimeters of mercury (mmHg) and is expressed as two numbers. For example, the optimal BP for an adult is 120 over 80, or 120/80. A pressure reading of 120 over 80 or lower is considered healthy. If the systolic number ranges above 120 to 139 or the diastolic number ranges above 80 to 89, a person is considered to have pre-hypertension. Systolic readings from 140 to 159 or diastolic readings from 90 to 99 are classified as stage 1 hypertension. Systolic measurements of 160 or above or diastolic measurements of 100 or above indicate the severe condition of stage 2 hypertension. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Hospital Anxiety and Depression Scale (HADS) | Baseline period and 3 months | The purpose of the HADS was to screen for clinically significant anxiety and depressive symptoms in medically ill patients. Content The HADS-A includes specific items that assess generalized anxiety including tension, worry, fear, panic, difficulties in relaxing, and restlessness. The total score for the HADS-A can range from 0 to 21. The following guidelines are recommended for the interpretation of scores: 0-7 for normal or no anxiety, 8-10 for mild anxiety, 11-14 for moderate anxiety, and 12-21 for severe anxiety. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06049186/registered